Table 6. Development of immune related adverse events.

Characteristic	Patients (n)
IRAE unrelated to underlying AD
• Patients who did not develop IRAE’s	33
• Patients who developed IRAE’s	9
IRAE’s experienced among 9 patients
• Grade 1–2	5
• Grade 3–4	4
ICI therapy during/after IRAE
• Continued	4
• Temporarily discontinued	1
• Permanently discontinued	4

IRAE(s), immune related adverse event(s); AD, autoimmune disease; ICI, immune checkpoint inhibitor; n, number of patients.